3 unknown, 2 completed. 5 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Unknown 3, Completed 2 |
| Phase 1 | 3 | Unknown 2, Completed 1 |
Follow Alzheimer Disease 5: new trials by email Literature Review of Alzheimer Disease 5 trials Research Report on Alzheimer Disease 5
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Safety and Immunogenicity of Ad5 COVID-19 Vaccines for Booster Use in Children Aged 6-17 Years. 1 Nebulized inhalation for booster groups, 2 Nebulized inhalation for booster groups, 3 Nebulized inhalation for booster groups - COVID-19 | Phase 2 | Unknown | Seventh Medical Center of PLA General Hospital | 410 | 2022-04-17 | 2023-04-13 |
| Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Placebo for Inhalation - COVID-19 | Phase 1 / Phase 2 | Completed | CanSino Biologics Inc. | 840 | 2021-04-21 | 2023-02-08 |
| A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo - COVID-19 | Phase 2 | Completed | CanSino Biologics Inc. | 480 | 2020-09-24 | 2022-10-31 |
| Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Placebo - COVID-19 | Phase 1 / Phase 2 | Unknown | CanSino Biologics Inc. | 696 | 2020-08-01 | 2020-07-02 |
| A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer Mobilan (M-VM3), Placebo - Prostate Cancer | Phase 1 / Phase 2 | Unknown | Panacela Labs LLC | 24 | 2016-07-01 | 2017-09-20 |
COVID-19 (4) · Adenoviridae Infections (1) · Prostatic Neoplasms (1)
Infections (5) · Virus Diseases (5) · Coronaviridae Infections (4) · Coronavirus Infections (4) · Lung Diseases (4) · Nidovirales Infections (4) · Pneumonia (4) · Pneumonia, Viral (4) · RNA Virus Infections (4) · Respiratory Tract Diseases (4) · Respiratory Tract Infections (4) · DNA Virus Infections (1) · Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1)
Inhalation (2)
CanSino Biologics Inc. (3) · Panacela Labs LLC (1) · Seventh Medical Center of PLA General Hospital (1)
China (3) · Canada (1) · Russia (1)
Fengcai Zhu, MSD (2) · Chen Dong (1) · Joanne M Langley, MD (1) · Scott A Halperin, MD (1)
PMID 34551104, PMID 37202147, PMID 37209700, PMID 37428653, PMID 38543926